-
1
-
-
33751267902
-
Acute myeloid leukaemia
-
DOI 10.1016/S0140-6736(06)69780-8, PII S0140673606697808
-
Estey E, Döhner H: Acute myeloid leukaemia. Lancet 2006, 368:1894-1907. (Pubitemid 44794525)
-
(2006)
Lancet
, vol.368
, Issue.9550
, pp. 1894-1907
-
-
Estey, E.1
Dohner, H.2
-
2
-
-
58149388069
-
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group
-
Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W: Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009, 27:61-69.
-
(2009)
J Clin Oncol
, vol.27
, pp. 61-69
-
-
Büchner, T.1
Berdel, W.E.2
Haferlach, C.3
Haferlach, T.4
Schnittger, S.5
Müller-Tidow, C.6
Braess, J.7
Spiekermann, K.8
Kienast, J.9
Staib, P.10
Grüneisen, A.11
Kern, W.12
Reichle, A.13
Maschmeyer, G.14
Aul, C.15
Lengfelder, E.16
Sauerland, M.C.17
Heinecke, A.18
Wörmann, B.19
Hiddemann, W.20
more..
-
3
-
-
79952086942
-
Therapeutic advances in acute myeloid leukemia
-
Burnett A, Wetzler M, Löwenberg B: Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011, 29:487-494.
-
(2011)
J Clin Oncol
, vol.29
, pp. 487-494
-
-
Burnett, A.1
Wetzler, M.2
Löwenberg, B.3
-
4
-
-
84867099700
-
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach
-
Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, Råcil Z, Rowe JM, Russell N, Mohty M, Löwenberg B, Socié G, Niederwieser D, Ossenkoppele GJ: The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.Nat Rev. Clin Oncol 2012, 9:579-590.
-
(2012)
Nat Rev. Clin Oncol
, vol.9
, pp. 579-590
-
-
Cornelissen, J.J.1
Gratwohl, A.2
Schlenk, R.F.3
Sierra, J.4
Bornhäuser, M.5
Juliusson, G.6
Råcil, Z.7
Rowe, J.M.8
Russell, N.9
Mohty, M.10
Löwenberg, B.11
Socié, G.12
Niederwieser, D.13
Ossenkoppele, G.J.14
-
5
-
-
33646404606
-
Age and acute myeloid leukemia
-
Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH: Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
-
(2006)
Blood
, vol.107
, pp. 3481-3485
-
-
Appelbaum, F.R.1
Gundacker, H.2
Head, D.R.3
Slovak, M.L.4
Willman, C.L.5
Godwin, J.E.6
Anderson, J.E.7
Petersdorf, S.H.8
-
6
-
-
78649486856
-
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
-
Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ: Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010, 116:4422-4429.
-
(2010)
Blood
, vol.116
, pp. 4422-4429
-
-
Kantarjian, H.1
Ravandi, F.2
O'Brien, S.3
Cortes, J.4
Faderl, S.5
Garcia-Manero, G.6
Jabbour, E.7
Wierda, W.8
Kadia, T.9
Pierce, S.10
Shan, J.11
Keating, M.12
Freireich, E.J.13
-
7
-
-
33846433493
-
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
-
DOI 10.1111/j.1365-2141.2006.06476.x
-
Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H: The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007, 136:624-627. (Pubitemid 46148199)
-
(2007)
British Journal of Haematology
, vol.136
, Issue.4
, pp. 624-627
-
-
Giles, F.J.1
Borthakur, G.2
Ravandi, F.3
Faderl, S.4
Verstovsek, S.5
Thomas, D.6
Wierda, W.7
Ferrajoli, A.8
Kornblau, S.9
Pierce, S.10
Albitar, M.11
Cortes, J.12
Kantarjian, H.13
-
8
-
-
66149148673
-
Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
-
Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, Tidefelt U, Wahlin A, Höglund M: Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-4187.
-
(2009)
Blood
, vol.113
, pp. 4179-4187
-
-
Juliusson, G.1
Antunovic, P.2
Derolf, A.3
Lehmann, S.4
Möllgård, L.5
Stockelberg, D.6
Tidefelt, U.7
Wahlin, A.8
Höglund, M.9
-
9
-
-
81255175041
-
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment
-
Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH: Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011, 29:4417-4423.
-
(2011)
J Clin Oncol
, vol.29
, pp. 4417-4423
-
-
Walter, R.B.1
Othus, M.2
Borthakur, G.3
Ravandi, F.4
Cortes, J.E.5
Pierce, S.A.6
Appelbaum, F.R.7
Kantarjian, H.A.8
Estey, E.H.9
-
10
-
-
84860257685
-
Roles of histone deacetylases in epigenetic regulation: Emerging paradigms from studies with inhibitors
-
Delcuve GP, Khan DH, Davie JR: Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 2012, 4:5.
-
(2012)
Clin Epigenetics
, vol.4
, pp. 5
-
-
Delcuve, G.P.1
Khan, D.H.2
Davie, J.R.3
-
11
-
-
34548176264
-
Valproic acid for the treatment of myeloid malignancies
-
DOI 10.1002/cncr.22891
-
Kuendgen A, Gattermann N: Valproic acid for the treatment of myeloid malignancies. Cancer 2007, 110:943-954. (Pubitemid 47312858)
-
(2007)
Cancer
, vol.110
, Issue.5
, pp. 943-954
-
-
Kuendgen, A.1
Gattermann, N.2
-
12
-
-
0035992780
-
Valproate and valproate-analogues: Potent tools to fight against cancer
-
Blaheta RA, Nau H, Michaelis M, Cinatl J Jr: Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 2002, 9:1417-1433. (Pubitemid 34823024)
-
(2002)
Current Medicinal Chemistry
, vol.9
, Issue.15
, pp. 1417-1433
-
-
Blaheta, R.A.1
Nau, H.2
Michaelis, M.3
Cinatl Jr., J.4
-
13
-
-
18244383806
-
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
-
DOI 10.1093/emboj/20.24.6969
-
Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978. (Pubitemid 34062289)
-
(2001)
EMBO Journal
, vol.20
, Issue.24
, pp. 6969-6978
-
-
Gottlicher, M.1
Minucci, S.2
Zhu, P.3
Kramer, O.H.4
Schimpf, A.5
Giavara, S.6
Sleeman, J.P.7
Lo, C.F.8
Nervi, C.9
Pelicci, P.G.10
Heinzel, T.11
-
14
-
-
79751528245
-
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
-
Quintás-Cardama A, Santos FP, Garcia-Manero G: Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011, 25:226-235.
-
(2011)
Leukemia
, vol.25
, pp. 226-235
-
-
Quintás-Cardama, A.1
Santos, F.P.2
Garcia-Manero, G.3
-
15
-
-
79954592316
-
Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival
-
Study Alliance Leukemia Group
-
Tickenbrock L, Klein HU, Trento C, Hascher A, Göllner S, Bäumer N, Kuss R, Agrawal S, Bug G, Serve H, Thiede C, Ehninger G, Stadt UZ, McClelland M, Wang Y, Becker A, Koschmieder S, Berdel WE, Dugas M, Müller-Tidow C, Study Alliance Leukemia Group: Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. Leuk Res 2011, 35: 620-625.
-
(2011)
Leuk Res
, vol.35
, pp. 620-625
-
-
Tickenbrock, L.1
Klein, H.U.2
Trento, C.3
Hascher, A.4
Göllner, S.5
Bäumer, N.6
Kuss, R.7
Agrawal, S.8
Bug, G.9
Serve, H.10
Thiede, C.11
Ehninger, G.12
Stadt, U.Z.13
McClelland, M.14
Wang, Y.15
Becker, A.16
Koschmieder, S.17
Berdel, W.E.18
Dugas, M.19
Müller-Tidow, C.20
more..
-
16
-
-
27144475816
-
Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors
-
DOI 10.1038/sj.leu.2403910, PII 2403910
-
Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, Craddock C, Turner BM: Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005, 19:1751-1759. (Pubitemid 41486152)
-
(2005)
Leukemia
, vol.19
, Issue.10
, pp. 1751-1759
-
-
Bradbury, C.A.1
Khanim, F.L.2
Hayden, R.3
Bunce, C.M.4
White, D.A.5
Drayson, M.T.6
Craddock, C.7
Turner, B.M.8
-
17
-
-
34547663854
-
Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia
-
DOI 10.3324/haematol.10758
-
Bug G, Schwarz K, Schoch C, Kampfmann M, Henschler R, Hoelzer D, Ottmann OG, Ruthardt M: Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 2007, 92:542-545. (Pubitemid 350144299)
-
(2007)
Haematologica
, vol.92
, Issue.4
, pp. 542-545
-
-
Bug, G.1
Schwarz, K.2
Schoch, C.3
Kampfmann, M.4
Henschler, R.5
Hoelzer, D.6
Ottmann, O.G.7
Ruthardt, M.8
-
18
-
-
34547652768
-
Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia
-
DOI 10.1016/j.leukres.2007.03.012, PII S0145212607000963
-
Cheng YC, Lin H, Huang MJ, Chow JM, Lin S, Liu HE: Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia. Leuk Res 2007, 31:1403-1411. (Pubitemid 47212434)
-
(2007)
Leukemia Research
, vol.31
, Issue.10
, pp. 1403-1411
-
-
Cheng, Y.-C.1
Lin, H.2
Huang, M.-J.3
Chow, J.-M.4
Lin, S.5
Liu, H.E.6
-
19
-
-
33748997409
-
Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia
-
DOI 10.1158/0008-5472.CAN-05-2726
-
Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, Fiorini R, Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F, Pelicci PG, Nervi C: Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006, 66:8903-8911. (Pubitemid 44449209)
-
(2006)
Cancer Research
, vol.66
, Issue.17
, pp. 8903-8911
-
-
Cimino, G.1
Lo-Coco, F.2
Fenu, S.3
Travaglini, L.4
Finolezzi, E.5
Mancini, M.6
Nanni, M.7
Careddu, A.8
Fazi, F.9
Padula, F.10
Fiorini, R.11
Spiriti, M.A.A.12
Petti, M.C.13
Venditti, A.14
Amadori, S.15
Mandelli, F.16
Pelicci, P.G.17
Nervi, C.18
-
20
-
-
79960225779
-
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C
-
Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A: Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. Leuk Res 2011, 35: 991-997.
-
(2011)
Leuk Res
, vol.35
, pp. 991-997
-
-
Corsetti, M.T.1
Salvi, F.2
Perticone, S.3
Baraldi, A.4
De Paoli, L.5
Gatto, S.6
Pietrasanta, D.7
Pini, M.8
Primon, V.9
Zallio, F.10
Tonso, A.11
Alvaro, M.G.12
Ciravegna, G.13
Levis, A.14
-
21
-
-
84869115143
-
Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid
-
Forthun RB, Sengupta T, Skjeldam HK, Lindvall JM, McCormack E, Gjertsen BT, Nilsen H: Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS One 2012, 7:e48992.
-
(2012)
PLoS One
, vol.7
-
-
Forthun, R.B.1
Sengupta, T.2
Skjeldam, H.K.3
Lindvall, J.M.4
McCormack, E.5
Gjertsen, B.T.6
Nilsen, H.7
-
22
-
-
84858290309
-
Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment
-
Fredly H, Reikvam H, Gjertsen BT, Bruserud O: Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Am J Hematol 2012, 87:368-376.
-
(2012)
Am J Hematol
, vol.87
, pp. 368-376
-
-
Fredly, H.1
Reikvam, H.2
Gjertsen, B.T.3
Bruserud, O.4
-
23
-
-
77957295583
-
Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - A report of five case
-
Fredly H, Stapnes Bjørnsen C, Gjertsen BT, Bruserud Ø: Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - a report of five case. Hematology 2010, 15:338-343.
-
(2010)
Hematology
, vol.15
, pp. 338-343
-
-
Fredly, H.1
Stapnes Bjørnsen, C.2
Gjertsen, B.T.3
Bruserud, Ø.4
-
24
-
-
77956924038
-
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
-
Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P, Craddock C: Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010, 116:1908-1918.
-
(2010)
Blood
, vol.116
, pp. 1908-1918
-
-
Goodyear, O.1
Agathanggelou, A.2
Novitzky-Basso, I.3
Siddique, S.4
McSkeane, T.5
Ryan, G.6
Vyas, P.7
Cavenagh, J.8
Stankovic, T.9
Moss, P.10
Craddock, C.11
-
25
-
-
74849120227
-
Valproic acid exerts differential effects on CXCR4 expression in leukemic cells
-
Gul H, Marquez-Curtis LA, Jahroudi N, Larratt LM, Janowska-Wieczorek A: Valproic acid exerts differential effects on CXCR4 expression in leukemic cells. Leuk Res 2010, 34:235-242.
-
(2010)
Leuk Res
, vol.34
, pp. 235-242
-
-
Gul, H.1
Marquez-Curtis, L.A.2
Jahroudi, N.3
Larratt, L.M.4
Janowska-Wieczorek, A.5
-
26
-
-
66649104180
-
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes
-
Hauswald S, Duque-Afonso J, Wagner MM, Schertl FM, Lubbert M, Peschel C, Keller U, Licht T: Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res 2009, 15:3705-3715.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3705-3715
-
-
Hauswald, S.1
Duque-Afonso, J.2
Wagner, M.M.3
Schertl, F.M.4
Lubbert, M.5
Peschel, C.6
Keller, U.7
Licht, T.8
-
27
-
-
42549108601
-
Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis
-
Iacomino G, Medici MC, Russo GL: Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis. Anticancer Res 2008, 28:855-864. (Pubitemid 351578930)
-
(2008)
Anticancer Research
, vol.28
, Issue.2 A
, pp. 855-864
-
-
Iacomino, G.1
Medici, M.C.2
Russo, G.L.3
-
28
-
-
58449117136
-
Elevated FOSB-expression; a potential marker of valproate sensitivity in AML
-
Khanim FL, Bradbury CA, Arrazi J, Hayden RE, Rye A, Basu S, MacWhannell A, Sawers A, Griffiths M, Cook M, Freeman S, Nightingale KP, Grimwade D, Falciani F, Turner BM, Bunce CM, Craddock C: Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. Br J Haematol 2009, 144:332-341.
-
(2009)
Br J Haematol
, vol.144
, pp. 332-341
-
-
Khanim, F.L.1
Bradbury, C.A.2
Arrazi, J.3
Hayden, R.E.4
Rye, A.5
Basu, S.6
MacWhannell, A.7
Sawers, A.8
Griffiths, M.9
Cook, M.10
Freeman, S.11
Nightingale, K.P.12
Grimwade, D.13
Falciani, F.14
Turner, B.M.15
Bunce, C.M.16
Craddock, C.17
-
29
-
-
70449449380
-
Human acute myeloid leukemia CD34 + CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells
-
Langenkamp U, Siegler U, Jörger S, Diermayr S, Gratwohl A, Kalberer CP, Wodnar-Filipowicz A: Human acute myeloid leukemia CD34 + CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells. Haematologica 2009, 94:1590-1594.
-
(2009)
Haematologica
, vol.94
, pp. 1590-1594
-
-
Langenkamp, U.1
Siegler, U.2
Jörger, S.3
Diermayr, S.4
Gratwohl, A.5
Kalberer, C.P.6
Wodnar-Filipowicz, A.7
-
30
-
-
84863781700
-
Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL
-
Leiva M, Moretti S, Soilihi H, Pallavicini I, Peres L, Mercurio C, Dal Zuffo R, Minucci S, de Thé H: Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia 2012, 26:1630-1637.
-
(2012)
Leukemia
, vol.26
, pp. 1630-1637
-
-
Leiva, M.1
Moretti, S.2
Soilihi, H.3
Pallavicini, I.4
Peres, L.5
Mercurio, C.6
Dal Zuffo, R.7
Minucci, S.8
De Thé, H.9
-
31
-
-
34248549656
-
Targeting AML1/ETO-histone deacetylase repressor complex: A novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells
-
DOI 10.1124/jpet.106.118406
-
Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z, BlumW, Chan KK, Perrotti D, Marcucci G: Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther 2007, 321:953-960. (Pubitemid 46762689)
-
(2007)
Journal of Pharmacology and Experimental Therapeutics
, vol.321
, Issue.3
, pp. 953-960
-
-
Liu, S.1
Klisovic, R.B.2
Vukosavljevic, T.3
Yu, J.4
Paschka, P.5
Huynh, L.6
Pang, J.7
Neviani, P.8
Liu, Z.9
Blum, W.10
Chan, K.K.11
Perrotti, D.12
Marcucci, G.13
-
32
-
-
77949615011
-
Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis
-
Lu X, Ohata K, Kondo Y, Espinoza JL, Qi Z, Nakao S: Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis. Cancer Sci 2010, 101:609-615.
-
(2010)
Cancer Sci
, vol.101
, pp. 609-615
-
-
Lu, X.1
Ohata, K.2
Kondo, Y.3
Espinoza, J.L.4
Qi, Z.5
Nakao, S.6
-
33
-
-
80051614029
-
Molecular marks for epigenetic identification of developmental and cancer stem cells
-
Patra SK, Deb M, Patra A: Molecular marks for epigenetic identification of developmental and cancer stem cells. Clin Epigenetics 2011, 2:27-53.
-
(2011)
Clin Epigenetics
, vol.2
, pp. 27-53
-
-
Patra, S.K.1
Deb, M.2
Patra, A.3
-
34
-
-
64849109372
-
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate
-
Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR: Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009, 23:641-648.
-
(2009)
Leukemia
, vol.23
, pp. 641-648
-
-
Poggi, A.1
Catellani, S.2
Garuti, A.3
Pierri, I.4
Gobbi, M.5
Zocchi, M.R.6
-
35
-
-
79952914715
-
Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia
-
Skavland J, Jørgensen KM, Hadziavdic K, Hovland R, Jonassen I, Bruserud Ø, Gjertsen BT: Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer J 2011, 1:e4.
-
(2011)
Blood Cancer J
, vol.1
-
-
Skavland, J.1
Jørgensen, K.M.2
Hadziavdic, K.3
Hovland, R.4
Jonassen, I.5
Bruserud, Ø.6
Gjertsen, B.T.7
-
36
-
-
78449301167
-
The effect of a histone deacetylase inhibitor - valproic acid - on nucleoli in human leukaemic myeloblasts
-
Smetana K, Zápotocký M: The effect of a histone deacetylase inhibitor - valproic acid - on nucleoli in human leukaemic myeloblasts. Folia Biol (Praha) 2010, 56: 201-205.
-
(2010)
Folia Biol (Praha)
, vol.56
, pp. 201-205
-
-
Smetana, K.1
Zápotocký, M.2
-
37
-
-
38449109278
-
Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors
-
Stapnes C, Ryningen A, Hatfield K, Øyan AM, Eide GE, Corbascio M, Kalland KH, Gjertsen BT, Bruserud Ø: Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. Int J Oncol 2007, 31:1529-1538.
-
(2007)
Int J Oncol
, vol.31
, pp. 1529-1538
-
-
Stapnes, C.1
Ryningen, A.2
Hatfield, K.3
Øyan, A.M.4
Eide, G.E.5
Corbascio, M.6
Kalland, K.H.7
Gjertsen, B.T.8
Bruserud, Ø.9
-
38
-
-
63849224411
-
Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway
-
St-Germain JR, Chen J, Li Q: Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway. Epigenetics 2008, 3:342-349.
-
(2008)
Epigenetics
, vol.3
, pp. 342-349
-
-
St.-Germain, J.R.1
Chen, J.2
Li, Q.3
-
39
-
-
29144481615
-
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia
-
Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N: Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005, 84(Suppl 1):61-66.
-
(2005)
Ann Hematol
, vol.84
, Issue.SUPPL. 1
, pp. 61-66
-
-
Kuendgen, A.1
Knipp, S.2
Fox, F.3
Strupp, C.4
Hildebrandt, B.5
Steidl, C.6
Germing, U.7
Haas, R.8
Gattermann, N.9
-
40
-
-
29744454120
-
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia
-
DOI 10.1002/cncr.21552
-
Kuendgen A, SchmidM, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106:112-119. (Pubitemid 43032555)
-
(2006)
Cancer
, vol.106
, Issue.1
, pp. 112-119
-
-
Kuendgen, A.1
Schmid, M.2
Schlenk, R.3
Knipp, S.4
Hildebrandt, B.5
Steidl, C.6
Germing, U.7
Haas, R.8
Dohner, H.9
Gattermann, N.10
-
41
-
-
0019407488
-
Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid
-
Breitman TR, Collins SJ, Keene BR: Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 1981, 57:1000-1004. (Pubitemid 11050800)
-
(1981)
Blood
, vol.57
, Issue.6
, pp. 1000-1004
-
-
Breitman, T.R.1
Collins, S.J.2
Keene, B.R.3
-
42
-
-
41949111045
-
Acute promyelocytic leukemia: From highly fatal to highly curable
-
Wang ZY, Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111: 2505-2515.
-
(2008)
Blood
, vol.111
, pp. 2505-2515
-
-
Wang, Z.Y.1
Chen, Z.2
-
43
-
-
80052914145
-
Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy
-
Park JH, Tallman MS: Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology 2011, 25:733-741.
-
(2011)
Oncology
, vol.25
, pp. 733-741
-
-
Park, J.H.1
Tallman, M.S.2
-
44
-
-
52149092181
-
Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia
-
Mrózek K, Bloomfield CD: Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. J Natl Cancer Inst Monogr 2008, 39:52-57.
-
(2008)
J Natl Cancer Inst Monogr
, vol.39
, pp. 52-57
-
-
Mrózek, K.1
Bloomfield, C.D.2
-
45
-
-
35348907310
-
PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia
-
Ohnishi K: PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int J Clin Oncol 2007, 12:313-317.
-
(2007)
Int J Clin Oncol
, vol.12
, pp. 313-317
-
-
Ohnishi, K.1
-
46
-
-
21744442937
-
The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells
-
DOI 10.1038/sj.leu.2403773
-
Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, Minden MD: The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 2005, 19:1161-1168. (Pubitemid 40945999)
-
(2005)
Leukemia
, vol.19
, Issue.7
, pp. 1161-1168
-
-
Trus, M.R.1
Yang, L.2
Suarez, S.F.3
Bordeleau, L.4
Jurisica, I.5
Minden, M.D.6
-
47
-
-
58849158362
-
Valproic acid and all-trans retinoic acid: Meta-analysis of a palliative treatment regimen in AML and MDS patients
-
Bellos F, Mahlknecht U: Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie 2008, 31:629-633.
-
(2008)
Onkologie
, vol.31
, pp. 629-633
-
-
Bellos, F.1
Mahlknecht, U.2
-
48
-
-
29144484694
-
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia
-
DOI 10.1002/cncr.21589
-
Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG: Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005, 104:2717-2725. (Pubitemid 41798282)
-
(2005)
Cancer
, vol.104
, Issue.12
, pp. 2717-2725
-
-
Bug, G.1
Ritter, M.2
Wassmann, B.3
Schoch, C.4
Heinzel, T.5
Schwarz, K.6
Romanski, A.7
Kramer, O.H.8
Kampfmann, M.9
Hoelzer, D.10
Neubauer, A.11
Ruthardt, M.12
Ottmann, O.G.13
-
49
-
-
20544471661
-
Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid
-
DOI 10.1002/cncr.21132
-
Pilatrino C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M, Familiari U, Cappia S, Pelicci PG, Lo Coco F, Saglio G, Guerrasio A: Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005, 104:101-109. (Pubitemid 40847757)
-
(2005)
Cancer
, vol.104
, Issue.1
, pp. 101-109
-
-
Pilatrino, C.1
Cilloni, D.2
Messa, E.3
Morotti, A.4
Giugliano, E.5
Pautasso, M.6
Familiari, U.7
Cappia, S.8
Pelicci, P.G.9
Lo, C.F.10
Saglio, G.11
Guerrasio, A.12
-
50
-
-
22544466164
-
Treatment of elderly acute myeloid leukemia with valproic acid and all-trans retinoic acid
-
Raffoux E, Chaibi P, Dombret H, Degos L: Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005, 90:986-988. (Pubitemid 41020306)
-
(2005)
Haematologica
, vol.90
, Issue.7
, pp. 986-988
-
-
Raffoux, E.1
Chaibi, P.2
Dombret, H.3
Degos, L.4
-
51
-
-
63349103376
-
A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid
-
Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O: A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 2009, 33:779-787.
-
(2009)
Leuk Res
, vol.33
, pp. 779-787
-
-
Ryningen, A.1
Stapnes, C.2
Lassalle, P.3
Corbascio, M.4
Gjertsen, B.T.5
Bruserud, O.6
-
52
-
-
0034554786
-
Report of an international working group to standardize response criteria for myelodysplastic syndromes
-
World Health Organization (WHO) international working group
-
Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL, World Health Organization (WHO) international working group: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
-
(2000)
Blood
, vol.96
, pp. 3671-3674
-
-
Cheson, B.D.1
Bennett, J.M.2
Kantarjian, H.3
Pinto, A.4
Schiffer, C.A.5
Nimer, S.D.6
Löwenberg, B.7
Beran, M.8
De Witte, T.M.9
Stone, R.M.10
Mittelman, M.11
Sanz, G.F.12
Wijermans, P.W.13
Gore, S.14
Greenberg, P.L.15
-
53
-
-
33745968917
-
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
-
DOI 10.1182/blood-2005-10-4149
-
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425. (Pubitemid 44061337)
-
(2006)
Blood
, vol.108
, Issue.2
, pp. 419-425
-
-
Cheson, B.D.1
Greenberg, P.L.2
Bennett, J.M.3
Lowenberg, B.4
Wijermans, P.W.5
Nimer, S.D.6
Pinto, A.7
Beran, M.8
De Witte, T.M.9
Stone, R.M.10
Mittelman, M.11
Sanz, G.F.12
Gore, S.D.13
Schiffer, C.A.14
Kantarjian, H.15
-
54
-
-
1542753559
-
Revised Recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
-
DOI 10.1200/JCO.2003.04.036
-
Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD, International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649. (Pubitemid 46594039)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.24
, pp. 4642-4649
-
-
Cheson, B.D.1
Bennett, J.M.2
Kopecky, K.J.3
Buchner, T.4
Willman, C.L.5
Estey, E.H.6
Schiffer, C.A.7
Doehner, H.8
Tallman, M.S.9
Lister, T.A.10
LoCocco, F.11
Willemze, R.12
Biondi, A.13
Hiddemann, W.14
Larson, R.A.15
Lowenberg, B.16
Sanz, M.A.17
Head, D.R.18
Ohno, R.19
Bloomfield, C.D.20
more..
-
55
-
-
33846988679
-
Treatment of acute promyelocytic leukemia by retinoids
-
Acute Promyelocytic Leukemia: Molecular Genetics, Mouse Models and Targeted Therapy
-
Fenaux P, Wang ZZ, Degos L: Treatment of acute promyelocytic leukemia by retinoids. Curr Top Microbiol Immunol 2007, 313:101-128. (Pubitemid 47400335)
-
(2007)
Current Topics in Microbiology and Immunology
, vol.313
, pp. 101-128
-
-
Fenaux, P.1
Wang, Z.Z.2
Degos, L.3
-
57
-
-
79956294708
-
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
-
Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW: Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011, 29:1987-1996.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1987-1996
-
-
Lübbert, M.1
Suciu, S.2
Baila, L.3
Rüter, B.H.4
Platzbecker, U.5
Giagounidis, A.6
Selleslag, D.7
Labar, B.8
Germing, U.9
Salih, H.R.10
Beeldens, F.11
Muus, P.12
Pflüger, K.H.13
Coens, C.14
Hagemeijer, A.15
Eckart Schaefer, H.16
Ganser, A.17
Aul, C.18
De Witte, T.19
Wijermans, P.W.20
more..
-
58
-
-
77449149374
-
Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia
-
Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF: Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28:556-561.
-
(2010)
J Clin Oncol
, vol.28
, pp. 556-561
-
-
Cashen, A.F.1
Schiller, G.J.2
O'Donnell, M.R.3
DiPersio, J.F.4
-
59
-
-
55749110754
-
Demethylating agents in myeloid malignancies
-
Garcia-Manero G: Demethylating agents in myeloid malignancies. Curr Opin Oncol 2008, 20:705-710.
-
(2008)
Curr Opin Oncol
, vol.20
, pp. 705-710
-
-
Garcia-Manero, G.1
-
60
-
-
62849104641
-
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
-
International Vidaza High-Risk MDS Survival Study Group
-
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High-Risk MDS Survival Study Group: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
-
(2009)
Lancet Oncol
, vol.10
, pp. 223-232
-
-
Fenaux, P.1
Mufti, G.J.2
Hellstrom-Lindberg, E.3
Santini, V.4
Finelli, C.5
Giagounidis, A.6
Schoch, R.7
Gattermann, N.8
Sanz, G.9
List, A.10
Gore, S.D.11
Seymour, J.F.12
Bennett, J.M.13
Byrd, J.14
Backstrom, J.15
Zimmerman, L.16
McKenzie, D.17
Beach, C.18
Silverman, L.R.19
-
61
-
-
77449149373
-
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia
-
Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
-
(2010)
J Clin Oncol
, vol.28
, pp. 562-569
-
-
Fenaux, P.1
Mufti, G.J.2
Hellström-Lindberg, E.3
Santini, V.4
Gattermann, N.5
Germing, U.6
Sanz, G.7
List, A.F.8
Gore, S.9
Seymour, J.F.10
Dombret, H.11
Backstrom, J.12
Zimmerman, L.13
McKenzie, D.14
Beach, C.L.15
Silverman, L.R.16
-
62
-
-
21844450205
-
Decitabine in acute myeloid leukemia
-
DOI 10.1053/j.seminhematol.2005.05.007, PII S0037196305000673, Emerging Role of Epigenetic Therapy: Focus on Decitabine
-
Lubbert M, Minden M: Decitabine in acute myeloid leukemia. Semin Hematol 2005, 42:S38-42. (Pubitemid 40961871)
-
(2005)
Seminars in Hematology
, vol.42
, Issue.SUPPL. 2
-
-
Lubbert, M.1
Minden, M.2
-
63
-
-
34548529948
-
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
-
Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G: Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007, 25:3884 -3891.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3884-3891
-
-
Blum, W.1
Klisovic, R.B.2
Hackanson, B.3
Liu, Z.4
Liu, S.5
Devine, H.6
Vukosavljevic, T.7
Huynh, L.8
Lozanski, G.9
Kefauver, C.10
Plass, C.11
Devine, S.M.12
Heerema, N.A.13
Murgo, A.14
Chan, K.K.15
Grever, M.R.16
Byrd, J.C.17
Marcucci, G.18
-
64
-
-
84855487228
-
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
-
Raffoux E, Cras A, Recher C, Boëlle PY, de Labarthe A, Turlure P, Marolleau JP, Reman O, Gardin C, Victor M, Maury S, Rousselot P, Malfuson JV, Maarek O, Daniel MT, Fenaux P, Degos L, Chomienne C, Chevret S, Dombret H: Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010, 1:34-42.
-
(2010)
Oncotarget
, vol.1
, pp. 34-42
-
-
Raffoux, E.1
Cras, A.2
Recher, C.3
Boëlle, P.Y.4
De Labarthe, A.5
Turlure, P.6
Marolleau, J.P.7
Reman, O.8
Gardin, C.9
Victor, M.10
Maury, S.11
Rousselot, P.12
Malfuson, J.V.13
Maarek, O.14
Daniel, M.T.15
Fenaux, P.16
Degos, L.17
Chomienne, C.18
Chevret, S.19
Dombret, H.20
more..
-
65
-
-
34948845116
-
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
-
DOI 10.1182/blood-2007-03-078576
-
Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G: Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110:2302-2308. (Pubitemid 47523148)
-
(2007)
Blood
, vol.110
, Issue.7
, pp. 2302-2308
-
-
Soriano, A.O.1
Yang, H.2
Faderl, S.3
Estrov, Z.4
Giles, F.5
Ravandi, F.6
Cortes, J.7
Wierda, W.G.8
Ouzounian, S.9
Quezada, A.10
Pierce, S.11
Estey, E.H.12
Issa, J.-P.J.13
Kantarjian, H.M.14
Garcia-Manero, G.15
-
66
-
-
33750530675
-
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
-
Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP: Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271-3279.
-
(2006)
Blood
, vol.108
, pp. 3271-3279
-
-
Garcia-Manero, G.1
Kantarjian, H.M.2
Sanchez-Gonzalez, B.3
Yang, H.4
Rosner, G.5
Verstovsek, S.6
Rytting, M.7
Wierda, W.G.8
Ravandi, F.9
Koller, C.10
Xiao, L.11
Faderl, S.12
Estrov, Z.13
Cortes, J.14
O'Brien, S.15
Estey, E.16
Bueso-Ramos, C.17
Fiorentino, J.18
Jabbour, E.19
Issa, J.P.20
more..
-
67
-
-
31444438952
-
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome
-
DOI 10.1038/sj.leu.2404050, PII 2404050
-
Maslak P, Chanel S, Camacho LH, Soignet S, Pandolfi PP, Guernah I, Warrell R, Nimer S: Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 2006, 20:212-217. (Pubitemid 43148657)
-
(2006)
Leukemia
, vol.20
, Issue.2
, pp. 212-217
-
-
Maslak, P.1
Chanel, S.2
Camacho, L.H.3
Soignet, S.4
Pandolfi, P.P.5
Guernah, I.6
Warrell, R.7
Nimer, S.8
-
68
-
-
79952262759
-
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
-
Wagner JM, Hackanson B, Lübbert M, Jung M: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 2010, 1:117-136.
-
(2010)
Clin Epigenetics
, vol.1
, pp. 117-136
-
-
Wagner, J.M.1
Hackanson, B.2
Lübbert, M.3
Jung, M.4
-
69
-
-
79952360031
-
Histone deacetylase inhibitors: Clinical implications for hematological malignancies
-
Tambaro FP, Dell'aversana C, Carafa V, Nebbioso A, Radic B, Ferrara F, Altucci L: Histone deacetylase inhibitors: clinical implications for hematological malignancies. Clin Epigenetics 2010, 1:25-44.
-
(2010)
Clin Epigenetics
, vol.1
, pp. 25-44
-
-
Tambaro, F.P.1
Dell'Aversana, C.2
Carafa, V.3
Nebbioso, A.4
Radic, B.5
Ferrara, F.6
Altucci, L.7
-
70
-
-
77953487591
-
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia
-
Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G: A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 2010, 150:72-82.
-
(2010)
Br J Haematol
, vol.150
, pp. 72-82
-
-
Kadia, T.M.1
Yang, H.2
Ferrajoli, A.3
Maddipotti, S.4
Schroeder, C.5
Madden, T.L.6
Holleran, J.L.7
Egorin, M.J.8
Ravandi, F.9
Thomas, D.A.10
Newsome, W.11
Sanchez-Gonzalez, B.12
Zwiebel, J.A.13
Espinoza-Delgado, I.14
Kantarjian, H.M.15
Garcia-Manero, G.16
-
71
-
-
79951874108
-
Vorinostat in acute myeloid leukemia and myelodysplastic syndromes
-
Prebet T, Vey N: Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs 2011, 20:287-295.
-
(2011)
Expert Opin Investig Drugs
, vol.20
, pp. 287-295
-
-
Prebet, T.1
Vey, N.2
-
72
-
-
70349633604
-
A phase 2 study of vorinostat in acute myeloid leukemia
-
Mayo P2C Phase II Consortium
-
Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD, Mayo P2C Phase II Consortium: A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009, 94:1375-1382.
-
(2009)
Haematologica
, vol.94
, pp. 1375-1382
-
-
Schaefer, E.W.1
Loaiza-Bonilla, A.2
Juckett, M.3
DiPersio, J.F.4
Roy, V.5
Slack, J.6
Wu, W.7
Laumann, K.8
Espinoza-Delgado, I.9
Gore, S.D.10
-
73
-
-
84860595206
-
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
-
Walter RB, Medeiros BC, Powell BL, Schiffer CA, Appelbaum FR, Estey EH: Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Haematologica 2012, 97:739-742.
-
(2012)
Haematologica
, vol.97
, pp. 739-742
-
-
Walter, R.B.1
Medeiros, B.C.2
Powell, B.L.3
Schiffer, C.A.4
Appelbaum, F.R.5
Estey, E.H.6
-
74
-
-
38949096781
-
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
-
DOI 10.1182/blood-2007-06-098061
-
Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066. (Pubitemid 351213383)
-
(2008)
Blood
, vol.111
, Issue.3
, pp. 1060-1066
-
-
Garcia-Manero, G.1
Yang, H.2
Bueso-Ramos, C.3
Ferrajoli, A.4
Cortes, J.5
Wierda, W.G.6
Faderl, S.7
Koller, C.8
Morris, G.9
Rosner, G.10
Loboda, A.11
Fantin, V.R.12
Randolph, S.S.13
Hardwick, J.S.14
Reilly, J.F.15
Chen, C.16
Ricker, J.L.17
Secrist, J.P.18
Richon, V.M.19
Frankel, S.R.20
Kantarjian, H.M.21
more..
-
75
-
-
84860229552
-
The epigenetic effects of butyrate: Potential therapeutic implications for clinical practice
-
Berni Canani R, Di Costanzo M, Leone L: The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. Clin Epigenetics 2012, 4:4.
-
(2012)
Clin Epigenetics
, vol.4
, pp. 4
-
-
Berni Canani, R.1
Di Costanzo, M.2
Leone, L.3
-
76
-
-
37249071337
-
Histone deacetylase inhibitors in cancer treatment: A review of the clinical toxicity and the modulation of gene expression in cancer cells
-
DOI 10.2174/138920107783018417
-
Bruserud Ø, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A: Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 2007, 8:388-400. (Pubitemid 350268198)
-
(2007)
Current Pharmaceutical Biotechnology
, vol.8
, Issue.6
, pp. 388-400
-
-
Bruserud, O.1
Stapnes, C.2
Ersvaer, E.3
Gjertsen, B.T.4
Ryningen, A.5
-
77
-
-
33144481148
-
Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML
-
DOI 10.1517/14728222.10.1.51
-
Bruserud Ø, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT: Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets 2006, 10:51-68. (Pubitemid 43263266)
-
(2006)
Expert Opinion on Therapeutic Targets
, vol.10
, Issue.1
, pp. 51-68
-
-
Bruserud, O.1
Stapnes, C.2
Tronstad, K.J.3
Ryningen, A.4
Anensen, N.5
Gjertsen, B.T.6
-
78
-
-
72449142349
-
Cytosine arabinoside: Metabolism, mechanisms of resistance and clinical pharmacology
-
Edited by Peters GJ. Totowa, NJ: Humana Press
-
Hubeek I, Kaspers G-J L, Ossenkoppele GJ, Peters GJ: Cytosine arabinoside: metabolism, mechanisms of resistance and clinical pharmacology. In Deoxynucleoside Analogs in Cancer Therapy. Edited by Peters GJ. Totowa, NJ: Humana Press; 2006:119-152
-
(2006)
Deoxynucleoside Analogs in Cancer Therapy
, pp. 119-152
-
-
Hubeek, I.1
Kaspers, G.-J.L.2
Ossenkoppele, G.J.3
Peters, G.J.4
-
80
-
-
65549090436
-
Acute myelogenous leukemia
-
Shipley JL, Butera JN: Acute myelogenous leukemia. Exp Hematol 2009, 37:649-658.
-
(2009)
Exp Hematol
, vol.37
, pp. 649-658
-
-
Shipley, J.L.1
Butera, J.N.2
-
81
-
-
0023500812
-
Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: A review
-
Bolwell BJ, Cassileth PA, Gale RP: Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. Leukemia 1987, 1:575-579. (Pubitemid 18005687)
-
(1987)
Leukemia
, vol.1
, Issue.8
, pp. 575-579
-
-
Bolwell, B.J.1
Cassileth, P.A.2
Gale, R.P.3
-
82
-
-
79960245246
-
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome
-
Burnett AK, Hills RK, Hunter A, Milligan D, Kell J, Wheatley K, Yin J, McMullin MF, Cahalin P, Craig J, Bowen D, Russell N: The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 2011, 25:1122-1127.
-
(2011)
Leukemia
, vol.25
, pp. 1122-1127
-
-
Burnett, A.K.1
Hills, R.K.2
Hunter, A.3
Milligan, D.4
Kell, J.5
Wheatley, K.6
Yin, J.7
McMullin, M.F.8
Cahalin, P.9
Craig, J.10
Bowen, D.11
Russell, N.12
-
83
-
-
79959702661
-
Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia
-
Gu LF, Zhang WG, Wang FX, Cao XM, Chen YX, He AL, Liu J, Ma XR: Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 2011, 137:997-1003.
-
(2011)
J Cancer Res Clin Oncol
, vol.137
, pp. 997-1003
-
-
Gu, L.F.1
Zhang, W.G.2
Wang, F.X.3
Cao, X.M.4
Chen, Y.X.5
He, A.L.6
Liu, J.7
Ma, X.R.8
-
84
-
-
55649106819
-
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia
-
Roboz GJ, Ritchie EK, Curcio T, Provenzano J, Carlin R, Samuel M, Wittenberg B, Mazumdar M, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ: Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer 2008, 113:2504-2511.
-
(2008)
Cancer
, vol.113
, pp. 2504-2511
-
-
Roboz, G.J.1
Ritchie, E.K.2
Curcio, T.3
Provenzano, J.4
Carlin, R.5
Samuel, M.6
Wittenberg, B.7
Mazumdar, M.8
Christos, P.J.9
Mathew, S.10
Allen-Bard, S.11
Feldman, E.J.12
-
85
-
-
27244459396
-
Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: A multicenter study of 112 Chinese patients
-
Li JM, Shen Y, Wu DP, Liang H, Jin J, Chen FY, Song YP, Song EY, Qiu XF, Hou M, Qiu ZC, Shen ZX: Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients. Int J Hematol 2005, 82:48 -54.
-
(2005)
Int J Hematol
, vol.82
, pp. 48-54
-
-
Li, J.M.1
Shen, Y.2
Wu, D.P.3
Liang, H.4
Jin, J.5
Chen, F.Y.6
Song, Y.P.7
Song, E.Y.8
Qiu, X.F.9
Hou, M.10
Qiu, Z.C.11
Shen, Z.X.12
-
86
-
-
71749097018
-
The combination of conventional chemotherapy with new targeted therapy in hematologic malignancies: The safety and efficiency of low-dose cytarabine supports its combination with new therapeutic agents in early clinical trials
-
Fredly H, Ersvaer E, Stapnes C, Gjertsen BT, Bruserud O: The combination of conventional chemotherapy with new targeted therapy in hematologic malignancies: the safety and efficiency of low-dose cytarabine supports its combination with new therapeutic agents in early clinical trials. Curr Cancer Ther Rev 2009, 5:243-255.
-
(2009)
Curr Cancer Ther Rev
, vol.5
, pp. 243-255
-
-
Fredly, H.1
Ersvaer, E.2
Stapnes, C.3
Gjertsen, B.T.4
Bruserud, O.5
-
87
-
-
33750322388
-
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia
-
DOI 10.1007/s11899-006-0025-4
-
Dingli D, Tefferi A: Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. Curr Hematol Malig Rep 2006, 1:69-74. (Pubitemid 44623867)
-
(2006)
Current Hematologic Malignancy Reports
, vol.1
, Issue.2
, pp. 69-74
-
-
Dingli, D.1
Tefferi, A.2
-
88
-
-
67349092776
-
Hydroxyurea and hydroxamic acid derivatives as antitumor drugs
-
Saban N, Bujak M: Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer Chemother Pharmacol 2009, 64:213-221.
-
(2009)
Cancer Chemother Pharmacol
, vol.64
, pp. 213-221
-
-
Saban, N.1
Bujak, M.2
-
89
-
-
31644448587
-
Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: The dark side of the moon
-
DOI 10.1093/annonc/mdj112
-
Latagliata R, Bongarzoni V, Carmosino I, Mengarelli A, Breccia M, Borza PA, D'Andrea M, D'Elia GM, Mecarocci S, Morano SG, Petti MC, Mandelli F, Alimena G: Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Ann Oncol 2006, 17:281-285. (Pubitemid 43167924)
-
(2006)
Annals of Oncology
, vol.17
, Issue.2
, pp. 281-285
-
-
Latagliata, R.1
Bongarzoni, V.2
Carmosino, I.3
Mengarelli, A.4
Breccia, M.5
Borza, P.A.6
D'Andrea, M.7
D'Elia, G.M.8
Mecarocci, S.9
Morano, S.G.10
Petti, M.C.11
Mandelli, F.12
Alimena, G.13
-
90
-
-
33947205565
-
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
-
DOI 10.1002/cncr.22496
-
Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-1124. (Pubitemid 46435390)
-
(2007)
Cancer
, vol.109
, Issue.6
, pp. 1114-1124
-
-
Burnett, A.K.1
Milligan, D.2
Prentice, A.G.3
Goldstone, A.H.4
McMullin, M.F.5
Hills, R.K.6
Wheatley, K.7
-
91
-
-
0041854628
-
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias
-
DOI 10.1007/s00277-003-0693-2
-
Petti MC, Tafuri A, Latagliata R, Aloe Spiriti MA, Montefusco E, Mancini M, Meloni G, Petrucci MT, Spadea A, Redi R, Alimena G, Mandelli F: High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. Ann Hematol 2003, 82:476-480. (Pubitemid 37062745)
-
(2003)
Annals of Hematology
, vol.82
, Issue.8
, pp. 476-480
-
-
Petti, M.C.1
Tafuri, A.2
Latagliata, R.3
Aloe, S.M.A.4
Montefusco, E.5
Mancini, M.6
Meloni, G.7
Petrucci, M.T.8
Spadea, A.9
Redi, R.10
Alimena, G.11
Mandelli, F.12
-
92
-
-
34547116188
-
Thiopurines, DNA damage, DNA repair and therapy-related cancer
-
Karran P: Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull 2006, 79-80:153-170.
-
(2006)
Br Med Bull
, vol.79-80
, pp. 153-170
-
-
Karran, P.1
-
93
-
-
84866631524
-
Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia
-
Adam De Beaumais T, Jacqz-Aigrain E: Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol 2012, 68:1233-1242.
-
(2012)
Eur J Clin Pharmacol
, vol.68
, pp. 1233-1242
-
-
Adam De Beaumais, T.1
Jacqz-Aigrain, E.2
-
94
-
-
33750445292
-
Treatment of acute myeloid leukemia patients aged more than 75 years: Results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG)
-
DOI 10.1080/10428190600733317, PII P862K8M222K03H70
-
Mori M, Ohta M, Miyata A, Higashihara M, Oshimi K, Kimura H, Yagasaki F, Sunami K: Treatment of acute myeloid leukemia patients aged more than 75 years: results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG). Leuk Lymphoma 2006, 47:2062-2069. (Pubitemid 44650081)
-
(2006)
Leukemia and Lymphoma
, vol.47
, Issue.10
, pp. 2062-2069
-
-
Mori, M.1
Ohta, M.2
Miyata, A.3
Higashihara, M.4
Oshimi, K.5
Kimura, H.6
Yagasaki, F.7
Sunami, K.8
-
95
-
-
29144468876
-
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: The Japan Adult Leukemia Study Group AML97 study
-
DOI 10.1002/cncr.21493
-
Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study: A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Cancer 2005, 104:2726-2734. (Pubitemid 41799616)
-
(2005)
Cancer
, vol.104
, Issue.12
, pp. 2726-2734
-
-
Miyawaki, S.1
Sakamaki, H.2
Ohtake, S.3
Emi, N.4
Yagasaki, F.5
Mitani, K.6
Matsuda, S.7
Kishimoto, Y.8
Miyazaki, Y.9
Asou, N.10
Matsushima, T.11
Takahashi, M.12
Ogawa, Y.13
Honda, S.14
Ohno, R.15
-
96
-
-
84894763978
-
The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
-
in press
-
Fredly H, Ersvaer E, Kittang AO, Tsykunova G, Gjertsen BT, Bruserud O: The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenetics. in press.
-
Clin Epigenetics
-
-
Fredly, H.1
Ersvaer, E.2
Kittang, A.O.3
Tsykunova, G.4
Gjertsen, B.T.5
Bruserud, O.6
-
97
-
-
84861359248
-
Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity
-
Lane S, Gill D, McMillan NA, Saunders N, Murphy R, Spurr T, Keane C, Fan HM, Mollee P: Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leuk Lymphoma 2012, 53:1077-1083.
-
(2012)
Leuk Lymphoma
, vol.53
, pp. 1077-1083
-
-
Lane, S.1
Gill, D.2
McMillan, N.A.3
Saunders, N.4
Murphy, R.5
Spurr, T.6
Keane, C.7
Fan, H.M.8
Mollee, P.9
-
98
-
-
84894876074
-
Hyperleukocytosis and leukapheresis: A single centre experience with regard to apheresis technique and efficiency and a review of previous studies of leukapheresis in the treatment of acute myeloid leukemia
-
in press
-
Bruserud O, Liseth K, Stamnesfet S, Cacic DL, Melve GK, Kristoffersen E, Hervig T, Reikvam H: Hyperleukocytosis and leukapheresis: a single centre experience with regard to apheresis technique and efficiency and a review of previous studies of leukapheresis in the treatment of acute myeloid leukemia. Transfus Med. in press.
-
Transfus Med
-
-
Bruserud, O.1
Liseth, K.2
Stamnesfet, S.3
Cacic, D.L.4
Melve, G.K.5
Kristoffersen, E.6
Hervig, T.7
Reikvam, H.8
-
99
-
-
33344474444
-
FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment
-
DOI 10.1182/blood-2005-08-3317
-
Cai D, Wang Y, Ottmann OG, Barth PJ, Neubauer A, Burchert A: FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. Blood 2006, 107:2094-2097. (Pubitemid 43289394)
-
(2006)
Blood
, vol.107
, Issue.5
, pp. 2094-2097
-
-
Cai, D.1
Wang, Y.2
Ottmann, O.G.3
Barth, P.J.4
Neubauer, A.5
Burchert, A.6
-
100
-
-
79955701085
-
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial
-
Candelaria M, Herrera A, Labardini J, González-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Pérez-Cárdenas E, de la Cruz-Hernández E, Arias-Bofill D, Vidal S, Cervera E, Dueñas-Gonzalez A: Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann Hematol 2011, 90:379-387.
-
(2011)
Ann Hematol
, vol.90
, pp. 379-387
-
-
Candelaria, M.1
Herrera, A.2
Labardini, J.3
González-Fierro, A.4
Trejo-Becerril, C.5
Taja-Chayeb, L.6
Pérez-Cárdenas, E.7
De La Cruz-Hernández, E.8
Arias-Bofill, D.9
Vidal, S.10
Cervera, E.11
Dueñas-Gonzalez, A.12
-
101
-
-
77955846351
-
Curcumin p38-dependently enhances the anticancer activity of valproic acid in human leukemia cells
-
Chen J, Wang G, Wang L, Kang J, Wang J: Curcumin p38-dependently enhances the anticancer activity of valproic acid in human leukemia cells. Eur J Pharm Sci 2010, 41:210-218.
-
(2010)
Eur J Pharm Sci
, vol.41
, pp. 210-218
-
-
Chen, J.1
Wang, G.2
Wang, L.3
Kang, J.4
Wang, J.5
-
102
-
-
47749083495
-
A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts
-
Fabre C, Grosjean J, Tailler M, Boehrer S, Ades L, Perfettini JL, de Botton S, Fenaux P, Kroemer G: A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle 2008, 7:2139-2145. (Pubitemid 352031516)
-
(2008)
Cell Cycle
, vol.7
, Issue.14
, pp. 2139-2145
-
-
Fabre, C.1
Grosjean, J.2
Tailler, M.3
Boehrer, S.4
Ades, L.5
Perfettini, J.-L.6
De Botton, S.7
Fenaux, P.8
Kroemer, G.9
-
103
-
-
65549136174
-
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells
-
Fuchs O, Provaznikova D, Marinov I, Kuzelova K, Spicka I: Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovasc Hematol Disord Drug Targets 2009, 9:62-77.
-
(2009)
Cardiovasc Hematol Disord Drug Targets
, vol.9
, pp. 62-77
-
-
Fuchs, O.1
Provaznikova, D.2
Marinov, I.3
Kuzelova, K.4
Spicka, I.5
-
104
-
-
84860750821
-
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia
-
McCormack E, Haaland I, Venås G, Forthun RB, Huseby S, Gausdal G, Knappskog S, Micklem DR, Lorens JB, Bruserud O, Gjertsen BT: Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia 2012, 26:910-917.
-
(2012)
Leukemia
, vol.26
, pp. 910-917
-
-
McCormack, E.1
Haaland, I.2
Venås, G.3
Forthun, R.B.4
Huseby, S.5
Gausdal, G.6
Knappskog, S.7
Micklem, D.R.8
Lorens, J.B.9
Bruserud, O.10
Gjertsen, B.T.11
-
105
-
-
84868352661
-
Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells
-
Nie D, Huang K, Yin S, Li Y, Xie S, Ma L, Wang X, Wu Y, Xiao J: Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells. Leuk Lymphoma 2012, 53:2487-2495.
-
(2012)
Leuk Lymphoma
, vol.53
, pp. 2487-2495
-
-
Nie, D.1
Huang, K.2
Yin, S.3
Li, Y.4
Xie, S.5
Ma, L.6
Wang, X.7
Wu, Y.8
Xiao, J.9
-
106
-
-
33745280074
-
Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: Mechanism and utility in enhancing selective growth inhibition by antifolates
-
DOI 10.1158/0008-5472.CAN-05-4048
-
Qi H, Ratnam M: Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Res 2006, 66:5875-5882. (Pubitemid 43927142)
-
(2006)
Cancer Research
, vol.66
, Issue.11
, pp. 5875-5882
-
-
Qi, H.1
Ratnam, M.2
-
107
-
-
84880787849
-
Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress
-
Ryningen A, Reikvam H, Nepstad I, Paulsen Rye K, Bruserud Ø: Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress. Bone Marrow Res 2012, 2012:329061.
-
(2012)
Bone Marrow Res
, vol.2012
, pp. 329061
-
-
Ryningen, A.1
Reikvam, H.2
Nepstad, I.3
Paulsen Rye, K.4
Bruserud, Ø.5
-
108
-
-
79960279715
-
Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells
-
Wang AH, Wei L, Chen L, Zhao SQ, Wu WL, Shen ZX, Li JM: Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells. Ann Hematol 2011, 90:917-931.
-
(2011)
Ann Hematol
, vol.90
, pp. 917-931
-
-
Wang, A.H.1
Wei, L.2
Chen, L.3
Zhao, S.Q.4
Wu, W.L.5
Shen, Z.X.6
Li, J.M.7
-
109
-
-
80051469142
-
Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor
-
Yu W, Wang J, Jin J, Qian W, Qian J, Cheng Y, Wang L: Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor. Leuk Res 2011, 35:1212-1218.
-
(2011)
Leuk Res
, vol.35
, pp. 1212-1218
-
-
Yu, W.1
Wang, J.2
Jin, J.3
Qian, W.4
Qian, J.5
Cheng, Y.6
Wang, L.7
-
110
-
-
68749099507
-
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
-
ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W: A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 2009, 23:1389-1397.
-
(2009)
Leukemia
, vol.23
, pp. 1389-1397
-
-
Ten Cate, B.1
Bremer, E.2
De Bruyn, M.3
Bijma, T.4
Samplonius, D.5
Schwemmlein, M.6
Huls, G.7
Fey, G.8
Helfrich, W.9
-
111
-
-
77954622997
-
Levels of care: Defining best supportive care in elderly patients with acute myeloid leukemia
-
Ritchie EK, Roboz GJ: Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia. Curr Hematol Malig Rep 2010, 5:95-100.
-
(2010)
Curr Hematol Malig Rep
, vol.5
, pp. 95-100
-
-
Ritchie, E.K.1
Roboz, G.J.2
-
112
-
-
0037158110
-
The outcomes and costs of acute myeloid leukemia among the elderly
-
DOI 10.1001/archinte.162.14.1597
-
Menzin J, Lang K, Earle CC, Kerney D, Mallick R: The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002, 162:1597-1603. (Pubitemid 34773427)
-
(2002)
Archives of Internal Medicine
, vol.162
, Issue.14
, pp. 1597-1603
-
-
Menzin, J.1
Lang, K.2
Earle, C.C.3
Kerney, D.4
Mallick, R.5
-
113
-
-
33750949551
-
Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches
-
Deschler B, de Witte T, Mertelsmann R, Lübbert M: Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006, 91:1513-1522. (Pubitemid 44736118)
-
(2006)
Haematologica
, vol.91
, Issue.11
, pp. 1513-1522
-
-
Deschler, B.1
De Witte, T.2
Mertelsmann, R.3
Lubbert, M.4
-
114
-
-
33845991508
-
Cancer vaccines for patients with acute myeloid leukemia - Definition of leukemia-associated antigens and current clinical protocols targeting these antigens
-
Greiner J, Döhner H, Schmitt M: Cancer vaccines for patients with acute myeloid leukemia-definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 2006, 91:1653-1661. (Pubitemid 46039635)
-
(2006)
Haematologica
, vol.91
, Issue.12
, pp. 1653-1661
-
-
Greiner, J.1
Dohner, H.2
Schmitt, M.3
-
115
-
-
57449084711
-
Anticancer immunotherapy in combination with proapoptotic therapy
-
Bruserud Ø, Ersvaer E, Olsnes A, Gjertsen BT: Anticancer immunotherapy in combination with proapoptotic therapy. Curr Cancer Drug Targets 2008, 8:666-675.
-
(2008)
Curr Cancer Drug Targets
, vol.8
, pp. 666-675
-
-
Bruserud, Ø.1
Ersvaer, E.2
Olsnes, A.3
Gjertsen, B.T.4
-
116
-
-
79954564425
-
Immunogenic apoptosis in human acute myeloid leukemia (AML): Primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis
-
Fredly H, Ersvær E, Gjertsen BT, Bruserud O: Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep 2011, 25: 1549-1556.
-
(2011)
Oncol Rep
, vol.25
, pp. 1549-1556
-
-
Fredly, H.1
Ersvær, E.2
Gjertsen, B.T.3
Bruserud, O.4
-
117
-
-
53149084152
-
Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells
-
Flandrin P, Guyotat D, Duval A, Cornillon J, Tavernier E, Nadal N, Campos L: Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones 2008, 13:357-364.
-
(2008)
Cell Stress Chaperones
, vol.13
, pp. 357-364
-
-
Flandrin, P.1
Guyotat, D.2
Duval, A.3
Cornillon, J.4
Tavernier, E.5
Nadal, N.6
Campos, L.7
-
118
-
-
33750354943
-
High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis [19]
-
DOI 10.1038/sj.leu.2404391, PII 2404391
-
Steiner K, Graf M, Hecht K, Reif S, Rossbacher L, Pfister K, Kolb HJ, Schmetzer HM, Multhoff G: High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis. Leukemia 2006, 20:2076-2079. (Pubitemid 44614913)
-
(2006)
Leukemia
, vol.20
, Issue.11
, pp. 2076-2079
-
-
Steiner, K.1
Graf, M.2
Hecht, K.3
Reif, S.4
Rossbacher, L.5
Pfister, K.6
Kolb, H.-J.7
Schmetzer, H.M.8
Multhoff, G.9
-
119
-
-
22144458740
-
Expression of heat-shock proteins is associated with major adverse
-
DOI 10.1016/j.leukres.2005.02.010, PII S014521260500086X
-
Thomas X, Campos L, Mounier C, Cornillon J, Flandrin P, Le QH, Piselli S, Guyotat D: Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 2005, 29:1049-1058. (Pubitemid 40982599)
-
(2005)
Leukemia Research
, vol.29
, Issue.9
, pp. 1049-1058
-
-
Thomas, X.1
Campos, L.2
Mounier, C.3
Cornillon, J.4
Flandrin, P.5
Le, Q.-H.6
Piselli, S.7
Guyotat, D.8
-
120
-
-
77950090840
-
Clinical correlation of circulating heat shock protein 70 in acute leukemia
-
Yeh CH, Tseng R, Hannah A, Estrov Z, Estey E, Kantarjian H, Albitar M: Clinical correlation of circulating heat shock protein 70 in acute leukemia. Leuk Res 2010, 34:605-609.
-
(2010)
Leuk Res
, vol.34
, pp. 605-609
-
-
Yeh, C.H.1
Tseng, R.2
Hannah, A.3
Estrov, Z.4
Estey, E.5
Kantarjian, H.6
Albitar, M.7
-
121
-
-
77954560509
-
Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: The hematological experience
-
Liseth K, Ersvaer E, Hervig T, Bruserud Ø: Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. J Biomed Biotechnol 2010, 2010:692097.
-
(2010)
J Biomed Biotechnol
, vol.2010
, pp. 692097
-
-
Liseth, K.1
Ersvaer, E.2
Hervig, T.3
Bruserud, Ø.4
-
122
-
-
58149229323
-
Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia
-
Alibhai SM, Leach M, Gupta V, Tomlinson GA, Brandwein JM, Saiz FS, Minden MD: Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia. Crit Rev Oncol Hematol 2009, 69:168-174.
-
(2009)
Crit Rev Oncol Hematol
, vol.69
, pp. 168-174
-
-
Alibhai, S.M.1
Leach, M.2
Gupta, V.3
Tomlinson, G.A.4
Brandwein, J.M.5
Saiz, F.S.6
Minden, M.D.7
-
123
-
-
1242307289
-
Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life
-
DOI 10.1016/S0305-7372(03)00142-7
-
Redaelli A, Stephens JM, Brandt S, Botteman MF, Pashos CL: Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treat Rev 2004, 30:103-117. (Pubitemid 38240090)
-
(2004)
Cancer Treatment Reviews
, vol.30
, Issue.1
, pp. 103-117
-
-
Redaelli, A.1
Stephens, J.M.2
Brandt, S.3
Botteman, M.F.4
Pashos, C.L.5
-
124
-
-
34548460707
-
The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults
-
DOI 10.1016/j.critrevonc.2007.07.003, PII S1040842807001382
-
Alibhai SM, Leach M, Kermalli H, Gupta V, Kowgier ME, Tomlinson GA, Brandwein J, Buckstein R, Minden MD: The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Crit Rev Oncol Hematol 2007, 64:19-30. (Pubitemid 47362737)
-
(2007)
Critical Reviews in Oncology/Hematology
, vol.64
, Issue.1
, pp. 19-30
-
-
Alibhai, S.M.H.1
Leach, M.2
Kermalli, H.3
Gupta, V.4
Kowgier, M.E.5
Tomlinson, G.A.6
Brandwein, J.7
Buckstein, R.8
Minden, M.D.9
-
125
-
-
15244363923
-
Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome
-
DOI 10.1038/sj.leu.2403289
-
Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, Galinsky I, Lee SJ: Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004, 18:809-816. (Pubitemid 38500200)
-
(2004)
Leukemia
, vol.18
, Issue.4
, pp. 809-816
-
-
Sekeres, M.A.1
Stone, R.M.2
Zahrieh, D.3
Neuberg, D.4
Morrison, V.5
De Angelo, D.J.6
Galinsky, I.7
Lee, S.J.8
-
126
-
-
24744446425
-
Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes
-
Wisløff F, Gulbrandsen N, Hjorth M, Lenhoff S, Fayers P: Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. Eur J Haematol 2005, 75:293-298.
-
(2005)
Eur J Haematol
, vol.75
, pp. 293-298
-
-
Wisløff, F.1
Gulbrandsen, N.2
Hjorth, M.3
Lenhoff, S.4
Fayers, P.5
-
127
-
-
33847065486
-
The Epigenomics of Cancer
-
DOI 10.1016/j.cell.2007.01.029, PII S0092867407001274
-
Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007, 128:683-692. (Pubitemid 46273572)
-
(2007)
Cell
, vol.128
, Issue.4
, pp. 683-692
-
-
Jones, P.A.1
Baylin, S.B.2
-
130
-
-
0032948005
-
Synergy of demethylation and histone deacetylase inhibition in the re- expression of genes silenced in cancer
-
DOI 10.1038/5047
-
Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21:103-107. (Pubitemid 29036293)
-
(1999)
Nature Genetics
, vol.21
, Issue.1
, pp. 103-107
-
-
Cameron, E.E.1
Bachman, K.E.2
Myohanen, S.3
Herman, J.G.4
Baylin, S.B.5
-
131
-
-
0037115392
-
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer
-
Fahrner JA, Eguchi S, Herman JG, Baylin SB: Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002, 62:7213-7218. (Pubitemid 36025241)
-
(2002)
Cancer Research
, vol.62
, Issue.24
, pp. 7213-7218
-
-
Fahrner, J.A.1
Eguchi, S.2
Herman, J.G.3
Baylin, S.B.4
-
132
-
-
84877152427
-
Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation
-
Bennemann K, Galm O, Wilop S, Schubert C, Brummendorf TH, Jost E: Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation. Clin Epigenetics 2012, 4:12.
-
(2012)
Clin Epigenetics
, vol.4
, pp. 12
-
-
Bennemann, K.1
Galm, O.2
Wilop, S.3
Schubert, C.4
Brummendorf, T.H.5
Jost, E.6
-
133
-
-
84856271833
-
Epigenetic abnormalities in myeloproliferative neoplasms: A target for novel therapeutic strategies
-
Mascarenhas J, Roper N, Chaurasia P, Hoffman R: Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenetics 2011, 2:197-212.
-
(2011)
Clin Epigenetics
, vol.2
, pp. 197-212
-
-
Mascarenhas, J.1
Roper, N.2
Chaurasia, P.3
Hoffman, R.4
|